247 related articles for article (PubMed ID: 24144808)
1. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis.
Wang J; Xie X; Wang X; Tang J; Pan Q; Zhang Y; Di M
Surg Oncol; 2013 Dec; 22(4):247-55. PubMed ID: 24144808
[TBL] [Abstract][Full Text] [Related]
2. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
3. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer.
Zumsteg ZS; Morrow M; Arnold B; Zheng J; Zhang Z; Robson M; Traina T; McCormick B; Powell S; Ho AY
Ann Surg Oncol; 2013 Oct; 20(11):3469-76. PubMed ID: 23686101
[TBL] [Abstract][Full Text] [Related]
4. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
Parker CC; Ampil F; Burton G; Li BD; Chu QD
Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
[TBL] [Abstract][Full Text] [Related]
5. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
6. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
7. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of correlation between breast cancer molecular subtypes and prognosis of patients receiving breast-conserving therapy].
Geng WW; Zhang B; Li DH; Liang XR; Cao XC
Zhonghua Yi Xue Za Zhi; 2013 May; 93(20):1571-3. PubMed ID: 24028726
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.
Kim S; Park HS; Kim JY; Ryu J; Park S; Kim SI
Yonsei Med J; 2016 Sep; 57(5):1192-8. PubMed ID: 27401651
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
11. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.
Lowery AJ; Kell MR; Glynn RW; Kerin MJ; Sweeney KJ
Breast Cancer Res Treat; 2012 Jun; 133(3):831-41. PubMed ID: 22147079
[TBL] [Abstract][Full Text] [Related]
12. Breast-conserving therapy: a viable option for young women with early breast cancer--evidence from a prospective study.
Xie Z; Wang X; Lin H; Wei W; Liu P; Xiao X; Xie X; Guan X; Yang M; Tang J
Ann Surg Oncol; 2014 Jul; 21(7):2188-96. PubMed ID: 24599412
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy.
Bhatti AB; Khan AI; Siddiqui N; Muzaffar N; Syed AA; Shah MA; Jamshed A
Asian Pac J Cancer Prev; 2014; 15(6):2577-81. PubMed ID: 24761867
[TBL] [Abstract][Full Text] [Related]
14. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
15. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
Tseng YD; Uno H; Hughes ME; Niland JC; Wong YN; Theriault R; Blitzblau RC; Moy B; Breslin T; Edge SB; Hassett MJ; Punglia RS
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):622-30. PubMed ID: 26461004
[TBL] [Abstract][Full Text] [Related]
16. Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy.
Pilewskie M; Ho A; Orell E; Stempel M; Chen Y; Eaton A; Patil S; Morrow M
Ann Surg Oncol; 2014 Apr; 21(4):1209-14. PubMed ID: 24327132
[TBL] [Abstract][Full Text] [Related]
17. [Safety of breast-conserving treatment for triple-negative breast cancer].
Wang L; Ouyang T; Wang T; Xie Y; Fan Z; Fan T; Li J
Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):947-52. PubMed ID: 26850668
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer is not a contraindication for breast conservation.
Adkins FC; Gonzalez-Angulo AM; Lei X; Hernandez-Aya LF; Mittendorf EA; Litton JK; Wagner J; Hunt KK; Woodward WA; Meric-Bernstam F
Ann Surg Oncol; 2011 Oct; 18(11):3164-73. PubMed ID: 21947595
[TBL] [Abstract][Full Text] [Related]
19. The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients.
O'Rorke MA; Murray LJ; Brand JS; Bhoo-Pathy N
Cancer Treat Rev; 2016 Jun; 47():12-21. PubMed ID: 27214603
[TBL] [Abstract][Full Text] [Related]
20. Outcome following local-regional recurrence in women with early-stage breast cancer: impact of biologic subtype.
Braunstein LZ; Niemierko A; Shenouda MN; Truong L; Sadek BT; Abi Raad R; Wong JS; Punglia RS; Taghian AG; Bellon JR
Breast J; 2015; 21(2):161-7. PubMed ID: 25559656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
